Drugs / Ad-CCL21-DC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01574222 | Oct 2011 → Mar 2017 | non-small cell lung carcinoma | VA Office of Research and Development | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad-CCL21-DC | “following intratumoral administration of autologous dendritic cells (DC) transduced with an adenoviral (Ad) vector expressing the CCL21 gene (Ad-CCL21-DC).” PMID 28468947 ↗ May 2017 |
| Modality | Vaccine | “Intratumoral vaccination with Ad-CCL21-DC resulted in (i) induction of systemic tumor antigen-specific immune responses” PMID 28468947 ↗ May 2017 |
| Route | Other | “by CT- or bronchoscopic-guided intratumoral injections” PMID 28468947 ↗ May 2017 |